Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

NextCure closes $93mm Series B round

Executive Summary

NextCure Inc. (immunotherapies) raised $93mm through its Series B round. Hillhouse Capital and Quan Capital led, and were joined by Bay City Capital, Surveyor Capital (Citadel), Ping An Ventures, Taiho Ventures, ArrowMark Partners, and NS Investment, along with returning backers Canaan Partners, Lilly Asia Ventures, OrbiMed Advisors, Pfizer, Sofinnova Ventures, and Alexandria Venture Investments. In connection with an alliance between the two that was announced earlier this month, Eli Lilly made a $15mm investment as part of the Series B. Proceeds will support continued development of lead candidates including preclinical NC318 (solid tumors) and will also fund NextCure's participation in the Lilly collaboration.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies